Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Influence of the Alpha-1-Adrenergic Receptor Blocker Doxazosin on Exercise-Induced Hyperkalemia in Hemodialysis Patients

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aim: Hyperkalemic responses to both physical exercise and α-adrenergic stimulation are enhanced in patients with terminal renal failure. α-Adrenergic blockade was found to protect against hyperkalemia during vigorous exercise in healthy men. The aim of the study was to examine the effects of the α-adrenergic blocker doxazosin on exercise-induced hyperkalemia in hemodialysis patients. Methods: In a randomized, placebo-controlled, crossover design study, 15 anuric, chronic hemodialysis patients were included. Doxazosin or placebo was given in a random order for 4 days before exercise. At the end of each phase of the study, a 30-min treadmill exercise test with a constant workload of 2 metabolic equivalents was performed followed by a 30-min recovery period. Results: The patients achieved 64 ± 3 and 62 ± 3% of maximal heart rate during the exercise test on doxazosin and placebo, respectively. The baseline plasma concentration of potassium was similar both on active treatment and on placebo (5.1 ± 0.2 mmol/l on doxazosin and 4.9 ± 0.1 mmol/l on placebo). The serum potassium concentration increased significantly and to a similar extent during the tests. The mean rates of potassium increment during exercise were 8.4 ± 1.5 µmol/l/min on doxazosin and 6.9 ± 1.3 µmol/l/min on placebo. During the recovery period, the serum potassium concentration significantly decreased in both arms of the study. There were no significant changes in plasma sodium, calcium, and phosphate levels during the tests. Hydrogen ion concentration in blood, serum insulin and glucose, and plasma aldosterone and renin activity were similar before the exercise tests. Conclusion: α-Adrenergic blockade does not modulate the hyperkalemic response to moderate physical exercise in patients with terminal renal failure.

          Related collections

          Author and article information

          Journal
          KBR
          Kidney Blood Press Res
          10.1159/issn.1420-4096
          Kidney and Blood Pressure Research
          S. Karger AG
          1420-4096
          1423-0143
          2002
          2002
          06 February 2002
          : 25
          : 1
          : 55-60
          Affiliations
          aDepartment of Nephrology, ‘Polish Mothers’ Memorial Hospital’ Research Institute, Łódź, bDepartment of Nephrology, Endocrinology and Metabolic Diseases, Silesian University, School of Medicine, Katowice, Poland
          Article
          49436 Kidney Blood Press Res 2002;25:55–60
          10.1159/000049436
          11834878
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 2, Tables: 2, References: 25, Pages: 6
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/49436
          Categories
          Original Paper

          Comments

          Comment on this article